Abstract
In recent years, drugs targeting tumor-specific molecules have achieved exciting efficacy in cancer therapy. However, due to the heterogeneity of cancers, current targeted therapy can only benefit a limited part of cancer patients. Thus, finding more broad spectrum targets is a study priority. Transmembrane protein CLDN18.2 is restrictedly expressed in gastric epithelial cells, while highly expressed and widely distributed in tumor tissues. The abnormal expression of CLDN18.2 is closely related to the occurrence and development of various cancers. Recent clinical trials have shown that CLDN18.2-targeting antibody IMAB362 works well alone or in combination with chemotherapy, indicating great potential of CLDN18.2 for cancer targeted therapy. This article reviews the biological characteristics of CLDN18.2 and its recent research progress in cancer targeted therapy. Key words: Carcinoma; Molecular targeted therapy; CLDN18.2
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
